Table 1.
Patient characteristics
| Number of patients screened | 28 |
| Treated and evaluable | 25 |
| Age (years) | |
| Median | 58 |
| Range | 31-79 |
| Performance statusa | |
| 0 | 18 (72%) |
| 1 | 5 (20%) |
| 2 | 2 (8%) |
| Primary disease sitea | |
| Ovary | 18 (72%) |
| Peritoneum | 7 (28%) |
| Histological subtype | |
| Serous adenocarcinoma | 22 |
| Clear cell | 1 |
| Mixed | 1 |
| Undifferentiated | 1 |
| Number of prior cytotoxic chemotherapya | |
| 1 | 5 (20%) |
| 2 | 20 (80%) |
| Platinum resistantb (0-6 months) | 16 |
| Platinum sensitive (6-12 months) | 9 |
| Time since initial diagnosis (months) | |
| Median | 15.9 |
| Range | 5-52 |
a
Percentages are based on the total number of all treated subjects.
b
Platinum-free interval refers to time from initial therapy to first relapse.